Needham & Company LLC Reiterates Hold Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Share on StockTwits

Needham & Company LLC reissued their hold rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Wednesday morning, AnalystRatings.com reports.

Several other analysts have also recently commented on BCRX. HC Wainwright restated a buy rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, August 8th. BidaskClub cut shares of BioCryst Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, October 4th. Finally, ValuEngine cut shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $9.64.

Shares of NASDAQ:BCRX traded down $0.03 during trading hours on Wednesday, hitting $2.03. The company’s stock had a trading volume of 1,337,600 shares, compared to its average volume of 1,473,949. The company has a market capitalization of $224.19 million, a price-to-earnings ratio of -2.07 and a beta of 1.86. BioCryst Pharmaceuticals has a 52 week low of $1.95 and a 52 week high of $9.95. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The firm’s fifty day moving average price is $2.53 and its 200 day moving average price is $3.71.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. The business had revenue of $1.78 million for the quarter, compared to analyst estimates of $4.54 million. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -1.23 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. BlackRock Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 2.6% in the 2nd quarter. BlackRock Inc. now owns 8,925,891 shares of the biotechnology company’s stock valued at $33,831,000 after purchasing an additional 228,525 shares during the period. University of Notre Dame DU Lac acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $1,854,000. Invesco Ltd. raised its position in BioCryst Pharmaceuticals by 63.9% during the second quarter. Invesco Ltd. now owns 1,446,732 shares of the biotechnology company’s stock worth $5,483,000 after acquiring an additional 563,822 shares during the period. DekaBank Deutsche Girozentrale raised its position in BioCryst Pharmaceuticals by 63.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 63,000 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 24,500 shares during the period. Finally, Morgan Stanley raised its position in BioCryst Pharmaceuticals by 285.1% during the second quarter. Morgan Stanley now owns 1,412,653 shares of the biotechnology company’s stock worth $5,354,000 after acquiring an additional 1,045,869 shares during the period. Institutional investors and hedge funds own 90.67% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Recommended Story: Outstanding Shares

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.